Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday

Aura Biosciences (NASDAQ:AURA) will likely be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Aura Biosciences to post earnings of ($0.43) per share for the quarter.

Aura Biosciences Stock Up 1.1 %

Aura Biosciences stock opened at $7.50 on Monday. The company has a fifty day simple moving average of $7.66 and a 200-day simple moving average of $8.67. The firm has a market capitalization of $374.63 million, a price-to-earnings ratio of -4.34 and a beta of 0.30. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38.

Insiders Place Their Bets

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 23,045 shares of company stock valued at $177,242 in the last three months. 5.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.